0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A novel jamming phase diagram links tumor invasion to non-equilibrium phase separation

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          It is well established that the early malignant tumor invades surrounding extracellular matrix (ECM) in a manner that depends upon material properties of constituent cells, surrounding ECM, and their interactions. Recent studies have established the capacity of the invading tumor spheroids to evolve into coexistent solid-like, fluid-like, and gas-like phases. Using breast cancer cell lines invading into engineered ECM, here we show that the spheroid interior develops spatial and temporal heterogeneities in material phase which, depending upon cell type and matrix density, ultimately result in a variety of phase separation patterns at the invasive front. Using a computational approach, we further show that these patterns are captured by a novel jamming phase diagram. We suggest that non-equilibrium phase separation based upon jamming and unjamming transitions may provide a unifying physical picture to describe cellular migratory dynamics within, and invasion from, a tumor.

          Graphical abstract

          Highlights

          • Tumor spheroids invading into a 3D matrix exhibit coexistent material phases

          • Invasion leads to spatiotemporal heterogeneities consistent with jamming dynamics

          • Phase separation patterns are captured by a model-based jamming phase diagram

          • Effective thermodynamic variables T eff and P conf capture cell and matrix properties

          Abstract

          Biophysics; Cancer; Mechanobiology

          Related collections

          Most cited references91

          • Record: found
          • Abstract: found
          • Article: not found

          Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

          Triple-negative breast cancer (TNBC) is a highly diverse group of cancers, and subtyping is necessary to better identify molecular-based therapies. In this study, we analyzed gene expression (GE) profiles from 21 breast cancer data sets and identified 587 TNBC cases. Cluster analysis identified 6 TNBC subtypes displaying unique GE and ontologies, including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype. Further, GE analysis allowed us to identify TNBC cell line models representative of these subtypes. Predicted "driver" signaling pathways were pharmacologically targeted in these cell line models as proof of concept that analysis of distinct GE signatures can inform therapy selection. BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin. M and MSL subtypes were enriched in GE for epithelial-mesenchymal transition, and growth factor pathways and cell models responded to NVP-BEZ235 (a PI3K/mTOR inhibitor) and dasatinib (an abl/src inhibitor). The LAR subtype includes patients with decreased relapse-free survival and was characterized by androgen receptor (AR) signaling. LAR cell lines were uniquely sensitive to bicalutamide (an AR antagonist). These data may be useful in biomarker selection, drug discovery, and clinical trial design that will enable alignment of TNBC patients to appropriate targeted therapies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Triple-negative breast cancer: clinical features and patterns of recurrence.

            To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer. We studied a cohort of 1,601 patients with breast cancer, diagnosed between January 1987 and December 1997 at Women's College Hospital in Toronto. Triple-negative breast cancers were defined as those that were estrogen receptor negative, progesterone receptor negative, and HER2neu negative. The prognostic significance of triple-negative breast cancer was explored. The median follow-up time of the 1,601 women was 8.1 years. One hundred and eighty of 1,601 patients (11.2%) had triple-negative breast cancer. Compared with other women with breast cancer, those with triple-negative breast cancer had an increased likelihood of distant recurrence (hazard ratio, 2.6; 95% confidence interval, 2.0-3.5; P < 0.0001) and death (hazard ratio, 3.2; 95% confidence interval, 2.3-4.5; P < 0.001) within 5 years of diagnosis but not thereafter. The pattern of recurrence was also qualitatively different; among the triple-negative group, the risk of distant recurrence peaked at approximately 3 years and declined rapidly thereafter. Among the "other" group, the recurrence risk seemed to be constant over the period of follow-up. Triple-negative breast cancers have a more aggressive clinical course than other forms of breast cancer, but the adverse effect is transient.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              EMT in cancer

              Similar to embryonic development, changes in cell phenotypes defined as an epithelial to mesenchymal transition (EMT) have been shown to play a role in the tumorigenic process. Although the first description of EMT in cancer was in cell cultures, evidence for its role in vivo is now widely reported but also actively debated. Moreover, current research has exemplified just how complex this phenomenon is in cancer, leaving many exciting, open questions for researchers to answer in the future. With these points in mind, we asked four scientists for their opinions on the role of EMT in cancer and the challenges faced by scientists working in this fast-moving field.
                Bookmark

                Author and article information

                Contributors
                Journal
                iScience
                iScience
                iScience
                Elsevier
                2589-0042
                12 October 2021
                19 November 2021
                12 October 2021
                : 24
                : 11
                : 103252
                Affiliations
                [1 ]Department of Environmental Science, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
                [2 ]Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA
                [3 ]Department of Bioengineering, University of Texas at Dallas, Richardson, TX 75080, USA
                [4 ]Thayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA
                [5 ]Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
                [6 ]Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA
                [7 ]Howard Hughes Medical Institute, Boston University, Boston, MA 02115, USA
                [8 ]Department of Physics, University of Ottawa, Ottawa, ON K1N 6N5, Canada
                Author notes
                []Corresponding author jjf@ 123456harvard.edu
                [9]

                These authors contributed equally

                [10]

                Lead contact

                Article
                S2589-0042(21)01221-9 103252
                10.1016/j.isci.2021.103252
                8564056
                34755092
                1f4e5fb3-269d-4f24-81d0-d729a84c9ff8
                © 2021 The Authors

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                : 26 February 2021
                : 14 September 2021
                : 7 October 2021
                Categories
                Article

                biophysics,cancer,mechanobiology
                biophysics, cancer, mechanobiology

                Comments

                Comment on this article